BiotechTube

avelumab + Bempegaldesleukin + talazoparib + enzalutamide

Phase 1/2Terminated
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Conditions

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)

Trial Timeline

Dec 30, 2019 → Sep 29, 2020

NCT ID
NCT04052204

About avelumab + Bempegaldesleukin + talazoparib + enzalutamide

avelumab + Bempegaldesleukin + talazoparib + enzalutamide is a phase 1/2 stage product being developed by Astellas Pharma for Squamous Cell Carcinoma of the Head and Neck (SCCHN). The current trial status is terminated. This product is registered under clinical trial identifier NCT04052204. Target conditions include Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC).

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04052204Phase 1/2Terminated

Competing Products

20 competing products in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
33
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
51
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
Cemiplimab + CetuximabEli LillyPhase 2
52
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
52
BB-401Benitec BiopharmaPhase 2
44
Ramucirumab + PaclitaxelEli LillyPhase 2
52
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
44
CT-P51 + EU-approved KeytrudaCelltrionPhase 3
77
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
41
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
77
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
41
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
33
Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3
77
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
77
Avelumab + enfortumab vedotinAstellas PharmaPhase 2
52
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
52
Drug Combination TherapySun PharmaceuticalPhase 2
52
Lenvatinib + Pembrolizumab + Docetaxel + Capecitabine + Paclitaxel + Cetuximab + LenvatinibEisaiPhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85